Antihistamine use in children

Roisin Fitzsimons,1,2 Lauri-Ann van der Poel,1 William Thornhill,3 George du Toit,1,2 Neil Shah,4,5 Helen A Brough1,2

ABSTRACT
This review provides an overview of the use of antihistamines in children. We discuss types of histamine receptors and their mechanism of action, absorption, onset and duration of action of first-generation and second-generation H(1)-antihistamines, as well as elimination of H(1)-antihistamines which has important implications for dosing in children. The rationale for the use of H(1)-antihistamines is explored for the relief of histamine-mediated symptoms in a variety of allergic conditions including: non-anaphylactic allergic reactions, atopic eczema (AE), allergic rhinitis (AR) and conjunctivitis, food protein-induced gastrointestinal allergy and asthma prevention. Second-generation H(1)-antihistamines are preferable to first-generation H(1)-antihistamines in the management of non-anaphylactic allergic reactions, AR, AE and CSU due to: their better safety profile, including minimal cognitive and antimuscarinic side effects and a longer duration of action. We offer some guidance as to the choices of H(1)-antihistamines available currently and their use in specific clinical settings. H(1)-antihistamine class, availability, licensing, age and dosing administration, recommended indications in allergic conditions and modalities of delivery for the 12 more commonly used H(1)-antihistamines in children are also tabulated.

INTRODUCTION
H(1)-antihistamines are among the most commonly prescribed medicines in children.1 Indications include acute allergic reactions in food allergy, allergic rhinitis (AR) and chronic spontaneous urticaria (CSU); they are also used for relief of histamine-mediated symptoms, but are not the drug of first choice, in the context of atopic eczema (AE) and anaphylaxis. The International Study for Asthma and Allergies in Childhood (ISAAC) has shown a world-wide trend for increasing symptoms of eczema and AR in childhood.2 In the UK, the Phase 3 (2002–2003) ISAAC study found a 10.1% prevalence of AR symptoms and 16% eczema symptoms in 6-year-old to 7-year-old children.2 Hospital admissions for food allergic reactions in the UK have increased by 500% between 1990 and 2003.3 In the last decade, the body of knowledge of the safety and efficacy of H(1)-antihistamines has increased substantially.4–6

HISTAMINE AND THE ALLERGIC RESPONSE
Histamine is a fundamental mediator in the pathophysiology of allergic condition in the smooth muscle, mucosa and skin (figure 1). On allergen exposure, an antigen cross-links specific immunoglobulin E (IgE) bound to the surface of mast cells and basophils and leads to degranulation with release of histamine and other pro-inflammatory mediators. Once released, histamine binds to G-protein-coupled receptors on a wide variety of cells within the surrounding tissues and vasculature.

TYPES OF HISTAMINE RECEPTORS
Four types of histamine receptors have been identified, which have varying degrees of responsibility for mediating an allergic response. H1 and H2 receptors are present on a wide range of cells (endothelial, epithelial, smooth muscle, neurons and cells of the innate and acquired immune system) and when in an active state, stimulate both the early phase of an allergic response (vasodilatation leading to erythema, swelling and hypotension) and the late-phase response, by upregulating cytokine production and cell-adhesion molecules, leading to a proinflammatory state.4–5 H(2)-receptor antagonists, such as ranitidine, work primarily on gastric mucosa, inhibiting gastric secretion. H3 and H4 receptors are less widely expressed but are inducers of pruritus and proinflammatory immune
responses. The therapeutic potential of targeting these new histamine receptors is yet to be fully elucidated.

ANTIHISTAMINE DRUGS AND MECHANISM OF ACTION

Nobel Prize winner Daniel Bovet, a Swiss-born Italian pharmacologist, is best known for his synthesis and testing of antihistamines in 1937. Antihistamines were once considered histamine receptor antagonists; however, they have been reclassified as inverse agonists that have an affinity for G-protein-coupled histamine receptors, to which they bind, returning equilibrium to the cell and reducing the effects of an allergic response. H(1)-antihistamines, thereby, inhibit respiratory, vascular and gastrointestinal smooth muscle constriction and decrease histamine-activated salivary and lacrimal gland secretions.

H(1)-antihistamines are generally categorised as old or first-generation or new, second-generation H(1)-antihistamines. The first generation of H(1)-antihistamines have poor receptor selectivity for the H(1)-receptor, occupying muscarinic cholinergic, α-adrenergic, serotonin receptors and ion channels. Additionally, first-generation H(1)-antihistamines are lipophilic, facilitating crossing of the blood-brain barrier into the central nervous system. Studies looking at the binding to H(1)-receptors in the brain in adults have shown between 50% and 90% occupancy by first-generation H(1)-antihistamines, compared with 30% cetirizine and a negligible amount for fexofenadine using positron emission tomography. These older H(1)-antihistamines may therefore be used for nausea (promethazine), migraine (pizotifen) and as preoperative medication, but the multiple receptor binding also means potential for related adverse effects (table 1). In the 1980s, new H(1)-antihistamines were developed to be minimally sedating or non-sedating, with limited blood-brain barrier penetration by addition of a carboxylic moiety with a protonated amine, reducing the drug’s blood-brain barrier penetration capacity and increasing H(1)-selectivity. Consensus on the use of these second-generation H(1)-antihistamines was published in 2003. Some texts refer to the active metabolites derived from second-H(1)-generation antihistamines as ‘third-generation’ H(1)-antihistamines (desloratadine, levocetirizine and fexofenadine), but they are more commonly classified under the second-generation H(1)-antihistamine category.

PHARMACOKINETICS AND PHARMACODYNAMICS OF H(1)-ANTIHISTAMINES

Absorption

Despite the longevity of their use, little is known about the pharmacokinetics and pharmacodynamics of first-generation H(1)-antihistamines in young children and infants. Second-generation H(1)-antihistamines have been studied more extensively in older children and adults, and in the case of
Table 1  Summary of the more commonly used H(1)-antihistamines licensed for use in children

<table>
<thead>
<tr>
<th>First-generation H(1)-antihistamines</th>
<th>Proprietary forms</th>
<th>Availability</th>
<th>Licensed indication</th>
<th>Licensing age</th>
<th>Children’s dose (^4) (oral doses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorphenamine (Chlorpheniramine)</td>
<td>Non-proprietary Piriton Allerief</td>
<td>P GSL</td>
<td>Symptomatic relief of allergy such as hay fever, urticaria, food allergy, drug reactions, relief of itch associated with chickenpox</td>
<td>Liquid 1–18 years Tabs 6–18 years</td>
<td>1 month–2 years 1 mg twice daily 2–6 years 1 mg every 4–6 h, max. 6 mg daily 6–12 years 2 mg every 4–6 h, max. 12 mg daily 12–18 years 4 mg every 4–6 h, max. 24 mg daily</td>
</tr>
<tr>
<td>Hydroxyzine</td>
<td>Atarax Ucerax</td>
<td>POM Pruritus</td>
<td>1–18 years</td>
<td>6 months–6 years initially 5–15 mg at night, increased if necessary to 50 mg daily in 3–4 divided doses 6–12 years initially 15–25 mg at night, increased if necessary to 50–100 mg daily in 3–4 divided doses 12–18 years initially 25 mg at night, increased if necessary to 100 mg in 3–4 divided doses</td>
<td></td>
</tr>
<tr>
<td>Ketotifen</td>
<td>Zaditen eye drops—Zaditen</td>
<td>POM POM</td>
<td>Symptomatic relief of allergy, such as allergic rhinitis (AR) eye drops—seasonal allergic conjunctivitis</td>
<td>3–18 years</td>
<td>3–18 years 1 mg twice daily 3–18 years apply twice daily</td>
</tr>
<tr>
<td>Promethazine hydrochloride</td>
<td>Non-proprietary Phenegan</td>
<td>POM</td>
<td>Symptomatic relief of allergy, such as hay fever, insomnia associated with urticaria and pruritus</td>
<td>2–18 years</td>
<td>2–5 years 5 mg twice daily or 5–15 mg at night 5–10 years 5–10 mg twice daily or 10–25 mg at night 10–18 years 10–20 mg 2–3 times daily or 25 mg at night increased to 25 mg twice daily if necessary</td>
</tr>
<tr>
<td>Second-generation H(1)-antihistamines</td>
<td>Generally, the second-generation H(1)-antihistamines have little or no side effect of drowsiness or antimuscarinic effect.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetirizine</td>
<td>Non-proprietary Piriteze Benadryl for children</td>
<td>GSL P POM</td>
<td>Hay fever, chronic idiopathic urticaria, atopic eczema</td>
<td>2–18 years</td>
<td>1–2 years 250 (\mu)g/kg twice daily 2–6 years 2.5 mg twice daily 6–12 years 5 mg twice daily 12–18 years 10 mg once daily</td>
</tr>
<tr>
<td>Loratadine</td>
<td>Non-proprietary Loratadine Allerize, Claritin</td>
<td>GSL P POM</td>
<td>Symptomatic relief of allergy, such as hay fever, chronic idiopathic urticaria</td>
<td>2–18 years</td>
<td>2–12 years under 30 kg 5 mg once daily over 30 kg 10 mg once daily 12–18 years 10 mg once daily</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>Non-proprietary Telfast</td>
<td>POM</td>
<td>Symptomatic relief of seasonal AR symptomatic relief of chronic idiopathic urticaria</td>
<td>6–18 years</td>
<td>6–12 years 30 mg twice daily 12–18 years 120 mg once daily 12–18 years 180 mg once daily</td>
</tr>
</tbody>
</table>

Continued
Table 1  Continued

<table>
<thead>
<tr>
<th>Proprietary forms</th>
<th>Availability</th>
<th>Licensed indication</th>
<th>Licensing age</th>
<th>Children’s dose (oral doses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levocetirizine</td>
<td>Xyzal</td>
<td>Symptomatic relief of allergy, such as hay fever, urticaria</td>
<td>Liquid</td>
<td>2–6 years 1.25 mg twice daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2–18 years Tables</td>
<td>6–18 years 5 mg once daily</td>
</tr>
<tr>
<td>Desloratadine</td>
<td>Desloratadine (non-proprietary), Neoclarityn</td>
<td>Hay-fever, chronic idiopathic urticaria</td>
<td>1–18 years</td>
<td>1–6 years 1.25 mg once daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6–12 years 2.5 mg once daily</td>
<td>12–18 years 5 mg once daily</td>
</tr>
<tr>
<td>Olopatadine</td>
<td>Opatanol</td>
<td>Seasonal allergic conjunctivitis</td>
<td>3–18 years</td>
<td>Child 3–18 years apply twice daily; max. duration of treatment 4 months</td>
</tr>
<tr>
<td>Acrivastine</td>
<td>Non-proprietary Acrivastine, Benadryl allergy relief</td>
<td>Hay fever, chronic idiopathic urticaria</td>
<td>12–18 years</td>
<td>8 mg three times a day</td>
</tr>
<tr>
<td>Azelastine</td>
<td>Optilast, Rhinolast Dymista—-with fluticasone</td>
<td>Allergic conjunctivitis, seasonal allergic conjunctivitis Perennial conjunctivitisSeasonal and perennial AR Moderate to severe seasonal and perennial AR, if monotherapy with antihistamine or corticosteroid is inadequate</td>
<td>4–18 years 5–18 years 12–18 years</td>
<td>Child 4–18 years apply twice daily, increased if necessary to 4 times daily Child 12–18 years apply twice daily, increased if necessary to 4 times daily; max. duration of treatment 6 weeks 1 spray into each nostril twice daily Child 12–18 years 1 spray into each nostril twice daily</td>
</tr>
</tbody>
</table>

Availability based on UK licensing includes whether on prescription (POM), or over the counter medicines: including pharmacist only (P) and general sales list medicines (GSL), which varies depending on license, pack size and brands. The licensed age range also varies from brand to brand. The usual dosing for various age ranges is described at the time of publication. The Table comprises information from summary of product characteristics for each H(1)-antihistamine and other source references. 

cetirizine, several studies have been conducted in younger children and infants down to 6 months of age. Following oral administration of H (1)-antihistamines, absorption usually occurs between 1 and 3 h, defined as the time taken to reach peak plasma concentration (Tmax). In 11 children aged 6–16 years, chlorphenamine took between 1 and 6 h (median 3 h) to reach Tmax. Certain second-generation H (1)-antihistamines reach peak plasma concentrations more rapidly; for levocetirizine, the mean Tmax was between 1 and 1.2 h, and for cetirizine, the mean Tmax was 0.8–2 h, depending on the age of the child and dose administered. In children aged between 6 and 24 months administered a single 0.25 mg/kg dose of cetirizine, the Tmax was mean±SD 2.0±1.3 h. In children aged 5–12 years, those administered 5 mg cetirizine had a Tmax of 1.4±1.1 h, whereas those administered 10 mg cetirizine had a Tmax of 0.8±0.4 h. Thus, Tmax appears reduced by lower cetirizine dosage and possibly also by younger age (although these children also received a lower dose of the drug). Conversely, desloratadine and fexofenadine can take up to 3 h to reach Tmax. Food slows the absorption of H (1)-antihistamines.

ONSET AND DURATION OF ACTION
Absorption does not equate to onset of action, as this effect is exerted locally in the tissues. Thus, onset of action of H(1)-antihistamines has been studied by observing in vivo inhibition of cutaneous wheal and flare responses. Commonly used first-generation H (1)-antihistamines have been shown to inhibit a wheal and flare response from 1 h after administration in older children. Second-generation H (1)-antihistamines have a varied onset of action in older children ranging from 0.5 h for cetirizine to 1 h for fexofenadine, loratadine and levocetirizine. To date, we could find no studies assessing timing of inhibition of wheal and flare with the use of H (1)-antihistamines in preschool children and infants. Second-generation H(1)-antihistamines have a longer duration of action and longer plasma half-life than first-generation H(1)-antihistamines.

BIOTRANSFORMATION
All first-generation H(1)-antihistamines and most second-generation H(1)-antihistamines, undergo metabolism in the liver by the hepatic cytochrome P450 enzyme system. Loratadine undergoes extensive first-pass metabolism in the liver resulting in deconjugation to a pharmacologically active conjugated metabolite, desloratadine, and it is excreted as its conjugated metabolite, with <1% of its original substance being found in the urine. Cetirizine, levocetirizine and fexofenadine are not metabolised in the liver and are, therefore, excreted unchanged in the urine or faeces. Cetirizine is a metabolite of hydroxyzine and fexofenadine is the hydrochloride salt of terfenadine’s active metabolite; thus, both anti-histamines are already metabolites of an earlier H (1)-antihistamine.

There are a number of substances that are known to affect the hepatic cytochrome P450 enzyme system, either inhibiting or inducing its action, which in turn can affect the plasma concentrations of H (1)-antihistamines either causing toxicity or reducing their action. Appendix 1 in the British National Formulary for Children has an extensive list of interactions between H(1)-antihistamines and other substances, including worsening sedation (alcohol, opioid analgesics, anxiolytics and hypnotics), increased antimuscarinic effects (tricyclic and monoamine oxidase inhibitor antidepressants), increased risk of ventricular arrhythmias (β-blockers and antiarrhythmics) reduction in bioavailability (antacids for fexofenadine) and increased bioavailability (macrolide antibiotics, ketoconazole antifungal, antivirals and grapefruit juice for rupatadine). Grapefruit juice reduces fexofenadine bioavailability, due to direct inhibition of uptake by intestinal organic anion transporting polypeptide A. Sedative interactions apply to a lesser extent to second-generation than first-generation H(1)-antihistamines; in general, due to the wider safety margin of second-generation H (1)-antihistamines, interactions are less likely to lead to serious side effects.

TERMINAL ELIMINATION
Terminal elimination of H(1)-antihistamines varies depending on the drug and age of the individual. For most H(1)-antihistamines, information regarding dosing in children has been extrapolated from studies looking at the safety and efficacy in the adult population. Long-term-safety of cetirizine and levocetirizine, however, has been studied more extensively in younger children aged 12–24 months old. Cetirizine and its enantiomer, levocetirizine, are eliminated more rapidly in young children, where renal clearance is more rapid. This has implications for dosing in young children, and twice daily administration is recommended for cetirizine and levocetirizine to achieve efficacy in children up to 6 years of age (table 1). Renal impairment reduces H(1)-antihistamine clearance. Although H(1)-antihistamines are rapidly eliminated from plasma, there is a residual effect of up to 7 days from H(1)-receptor occupancy, continuing to have a local effect; this residual anti-inflammatory effect may be of therapeutic benefit when used for chronic allergic conditions, such as AR or CSU. In a study to evaluate the potential anti-inflammatory activities of the newer antihistamines, desloratadine dose-dependently inhibited specific cytokine release and the chemoattractants for human neutrophils and eosinophils. This in vitro work shows some promise, but
There are other published reports of possible anti-inflammatory effects mediated through the H1 receptor, especially with regular over intermittent use, thus, more studies are needed to evaluate the anti-inflammatory properties of H(1)-antihistamines in vivo.

MEASURING EFFICACY
There are no adequate objective measures of H (1)-antihistamine efficacy. Efficacy is subjective and is both patient-dependent and disease-dependent. Church and Maurer concluded that the clinical efficacy of an H(1)-antihistamine could not be predicted solely from knowledge of its in vitro potency, and that in vivo inhibition of wheal and flare was a more accurate reflection of efficacy. However, in vivo efficacy is influenced by metabolism and excretion, lipid solubility, the degree and strength of binding to proteins and structural elements, penetration into and accumulation in the tissues and the local concentration of histamine in the tissues. Simons et al conducted a prospective, randomised, placebo-controlled, double-blind, crossover, single-dose study to evaluate the onset and duration of action of cetirizine and loratadine in 15 children (mean age of 9 years); the authors concluded that cetirizine and loratadine were both effective antihistamines in children aged 12–24 months. For long-term conditions, the effect of H (1)-antihistamine may not be immediately apparent, and the use of quality of life (QoL) measures may facilitate a more accurate determination of efficacy, of which there are now several validated tools.

USE OF H(1)-ANTIHISTAMINES IN CLINICAL PRACTICE
Despite first-generation H(1)-antihistamines being in use for over 70 years, there are fewer studies assessing their pharmacodynamics and safety profile. Second-generation H(1)-antihistamines are the H (1)-antihistamines of choice for treatment of an allergic response due to their high selectivity for H (1)-receptors, efficacy and minimal side effects. There are several licensed indications for the use of H (1)-antihistamines in the paediatric population as described in table 1; however, we show our recommendations for their use in specific clinical settings (e.g. use in an emergency) in table 2. The most common route of administration of H (1)-antihistamines is oral, however, chlorphenamine can be administered intravenously and there are topical preparations available for ocular and nasal use for several H(1)-antihistamines. Age of licensed use in children and dosage are displayed in table 1; there are doses available from 1 year of age for cetirizine, although the official licencing is from 2 years of age. The safety and efficacy profiles outlined for cetirizine

Table 2
Summary of commonly used H(1)-antihistamines in children, recommendations for use in specific clinical settings and available modalities of administration

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorphenamine</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Hydroxyzine</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Ketotifen</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Promethazine</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cetirizine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Loratadine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Levocetirizine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Desloratadine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Olopatadine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Acrivastine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Azelastine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

*First-generation H(1)-antihistamines use in atopic eczema should be short-term (7–14 days).
At, allergic; AR, allergic rhinitis; CSU, chronic spontaneous urticaria; FPIGA, food protein-induced gastrointestinal allergy.
Pharmacy update

suggest that this can be administered in this younger age group.

ACUTE URTICARIA AND ALLERGIC REACTIONS
Emergency treatment of non-anaphylactic IgE-mediated hypersensitivity reactions
H(1)-antihistamines administered at the first sign of a non-anaphylactic allergic reaction may relieve immediate symptoms and possibly halt the progression onto a more severe allergic reaction, by inactivating the G-protein receptors and down-regulating the release of inflammatory mediators which, in turn, reduces the influx of inflammatory cells. The British Society of Allergy and Clinical Immunology (BSACI) allergy action plans (http://www.bsaci.org/about/download-paediatric-allergy-action-plans) defaults to cetirizine for acute non-anaphylactic allergic reactions.

ANAPHYLAXIS
During anaphylaxis, several inflammatory mediators are released from degranulating mast cells and basophils; however, histamine maintains a pivotal role in inducing anaphylaxis. In fact, the signs and symptoms of anaphylaxis can be reproduced solely by histamine infusion.24 However, adrenaline remains the emergency medication of choice in anaphylaxis. H(1)-antihistamines have a slower onset of action than intramuscular adrenaline and cannot block the effects of histamine once it has bound to the G-protein-coupled receptors on cells. Additionally, H(1)-antihistamines provide none of the cardiovascular benefits of adrenaline.

The UK Resuscitation Council Guidelines for the Management of Anaphylaxis recommends intravenous chlorphenamine to follow intramuscular adrenaline.24 A number of guidelines recommend the use of H(1)-antihistamines as an important treatment option in anaphylaxis. This recommendation is based on clinical experience but does not have a strong scientific basis; indeed, there might be no treatment effect, or the side effects might be worse than the treatment effect itself, particularly in the case of first-generation H(1)-antihistamines.25 A Cochrane review was unable to find any randomised controlled trials comparing H(1)-antihistamines with placebo in the management of anaphylaxis.26

ALLERGIC RHINITIS (AR) AND CONJUNCTIVITIS
AR reduces QoL and learning ability in children and is associated with poor examination performance in teenagers due to poor sleep quality and daytime somnolence; this has been shown to be compounded by first-generation H(1)-antihistamines but not by second-generation H(1)-antihistamines.25 A case-control study of 1834 students in the UK taking national examinations found that teenagers with untreated AR were 40% more likely to drop a grade or more compared with healthy teenagers.27

First-generation H(1)-antihistamines increased the affected number of teenagers more likely to drop a grade to 70%.27 The Allergic Rhinitis and its Impact on Asthma group (ARIA) recommend second-generation H(1)-antihistamines as the antihistamine treatment of choice for AR.18 Cetirizine, levocetirizine, fexofenadine and loratadine all have well-documented clinical efficacy in treating AR in children.13 28 The 2008 BSACI AR guidelines advise that the topical nasal H(1)-antihistamine azelastine is more effective in treating AR symptoms than oral H(1)-antihistamines, however, is not as effective in treating allergic conjunctivitis.29 Intranasal steroids are far superior to H(1)-antihistamine alone in the treatment of AR, but there are combination intranasal H(1)-antihistamine and steroid preparations showing good efficacy.30 For allergic conjunctivitis, olopatadine eye drops (through dual H(1)-antihistamine mast cell stabilisation effects) are superior to sodium chromoglycate with good cost effectiveness and fewer general practitioner attendances in the olopatadine group.31

ALLERGIC RHINITIS IN ASTHMA
A population-based study over 12 months from a UK General Practice database found that children with physician-diagnosed AR were more than twice as likely to be hospitalised for asthma compared with asthmatic children without AR.32 Treatment with intranasal steroids and/or second-generation H(1)-antihistamines in children with asthma and AR has been shown to significantly reduce the risk of emergency care and hospital admission due to asthma exacerbations.33 It may be, therefore, that—as part of the ‘united airway’ concept—treatment of AR and reduction in nasal allergic inflammation may deliver some benefits on lung function in asthmatic children.

ASTHMA PREVENTION
The Early Treatment of the Atopic Child (ETAC) study was a randomised controlled study on the prevention of asthma by twice daily administration of cetirizine in children aged 12–24 months with AE. There was no difference in the cumulative prevalence of asthma between groups overall; however, in a posthoc analysis, they found a 50% reduction in the development of asthma symptoms compared with the placebo group, in a subset of children sensitised to grass pollen or house dust mite.16 These findings could not be replicated in the Early Prevention of Asthma in Atopic Children (EPAAC) study, where young children with AE sensitised to grass pollen and house dust mite were treated with levocetirizine;17 thus, H(1)-antihistamines do not appear to have a role in the prevention of asthma.
INTERMITTENT AND CHRONIC COUGH
H(1)-antihistamines are not recommended as empiric treatment for chronic cough in children, contrasting with adult recommendations, unless postnasal drip is diagnosed in the context of AR. Since February 2009, the Medicines and Healthcare products Regulatory Agency in the UK has advised that cough and cold remedies containing certain ingredients, including first-generation H(1)-antihistamines, should no longer be used in children younger than 6 years of age, due to the unfavourable balance of benefit and risks.

CHRONIC SPONTANEOUS URTICARIA
CSU (previously known as chronic idiopathic urticaria) is defined as urticaria with daily, or almost daily, symptoms for more than 6 weeks. The recommended first-line treatment for CSU is second-generation H(1)-antihistamines. Data in adults comparing efficacy in CSU suggest using cetirizine over fexofenadine and levocetirizine over desloratadine and fexofenadine. If standard dosing is ineffective, increasing the daily dosage (by increasing frequency of dosage) up to fourfold may be recommended. Current limited data suggest that higher doses of levocetirizine and desloratadine are more effective in CSU unresponsive to standard doses and that higher than recommended doses of fexofenadine offers no greater efficacy in symptom control. In patients who still remain unresponsive, use of another non-sedating H(1)-antihistamine is recommended. Second-line therapies, such as leukotriene receptor antagonists, and H(2)-antihistamines, such as ranitidine (Zantac), may be added to H(1)-antihistamine treatment. These are sometimes used to treat CSU, as approximately 15% of cutaneous receptors are H(2)-receptors, but there is currently little published data on their efficacy in this context.

FOOD PROTEIN-INDUCED GASTROINTESTINAL ALLERGY
Food protein-induced gastrointestinal allergy (FPIGA) is non-IgE mediated and may respond to specific dietary exclusions. For some patients, dietary exclusions may need to be accompanied by medications, including antihistamines, to control ongoing symptoms. There are several small studies on the use of antihistamines and mast cell stabilisers to control gastrointestinal symptoms thought to be caused by the interplay between the enteric nervous system and the mucosal immune system of the intestine. Ketotifen fumarate, a first-generation H(1)-antihistamine, also has mast cell stabilisation effects and has been shown to have benefits in some patients with FPIGA. In a prospective study of 77 children, the additional benefit of ketotifen to carefully controlled elimination diets ranged from 52.1% improvement in abdominal pain but only 17.2% improvement in vomiting. The H(2)-antihistamine commonly used in FPIGA is ranitidine, better recognised for its acid suppressive effects acting through H(2)-receptor blockade. A word of caution is that there has been a reported increase in the incidence of food allergy associated with the use of excessive use of antacid treatments in both humans and animal models.

ATOPIECZEMA
Current National Institute for Health and Care Excellence (NICE) guidance for AE in children does not recommend the routine use of oral H(1)-antihistamines in the management of AE; however, a 1-month trial of a non-sedating H(1)-antihistamine may be offered to children with AE where there is severe itching or urticaria. NICE guidance recommends daily dose.

Key points
- The use of second-generation H(1)-antihistamines, such as cetirizine, loratadine and fexofenadine should be first-line therapy for the management of urticaria secondary to food allergic reactions, allergic rhinitis or chronic spontaneous urticaria (CSU) in children.
- Cetirizine has at least as quick an onset of action as chlorphenamine, and is our preferred choice of second-generation H(1)-antihistamine for non-anaphylactic food allergic reactions in children due the body of literature on safety and pharmacokinetics available on this drug. It is also available in syrup form.
- Intramuscular adrenaline is the treatment of choice in the management of anaphylaxis. There is currently insufficient evidence on the benefit of H(1)-antihistamines in the treatment of anaphylaxis.
- First-generation H(1)-antihistamines, such as chlorphenamine and hydroxyzine, are relatively non-specific and lipophilic and are more likely to lead to central nervous system effects. The sedative effect of first-generation H(1)-antihistamines may seem desirable or indicated (e.g. nocturnal relief in atopic eczema-related pruritis) but can disrupt sleep patterns and affect learning.
- Second-generation (non-sedating) H(1)-antihistamines are well tolerated over a long period, and have fewer adverse effects on cognition, although some patients may still experience sedation.
- High doses of second-generation H(1)-antihistamine are often necessary for symptomatic control of CSU and appear to be safe in up to four times the recommended daily dose.
- Emergency department-based comparative trials between first-generation and second-generation H(1)-antihistamines would be useful. Parenteral forms of second-generation H(1)-antihistamines are not currently available.
First-generation H(1)-antihistamines have been available since the 1980s and are of major therapeutic value in the management of allergic conditions and have been in use for 70 years. The second-generation (H) 1-antihistamines have been developed since the 1980s and are preferable for chronic use for 70 years. The second-generation (H) 1-antihistamines have been in use for 70 years. The second-generation (H) 1-antihistamines have been developed since the 1980s and are of major therapeutic value in the management of allergic conditions and have been in use for 70 years.

SUMMARY

H(1)-antihistamines are of major therapeutic value in the management of allergic conditions and have been in use for 70 years. The second-generation (H) 1-antihistamines have been available since the 1980s and should be used over first-generation (H) 1-antihistamines due to their more favourable side-effect profile, duration of action and safety record. While second-generation H(1)-antihistamines are preferable even for emergency medication in an allergic reaction, no parenteral formulation is available. Before treatment with any antihistamine is commenced, the child and family should be counselled in appropriate use, that is, age of licensed use, frequency and dosing, clinical effects and possible side effects—especially in the case of first-generation H(1)-antihistamines.

Contributors

HAB wrote the abstract, introduction, summary and questions, and critically reviewed and amended the manuscript and references as a whole. RF wrote the sections on clinical use of antihistamines. L-AvdP created figure 1 and wrote the sections on clinical use of antihistamines and the Key Points. WT created table 1 and the text for adverse effects of antihistamines. GdT wrote the section on chronic spontaneous urticaria and NS wrote the section on food protein-induced gastrointestinal allergy.

Competing interests

HAB has received research grant support from Thermofisher Scientific, Stallergenes and Meridian Foods, conference fees from Meda, Thermofisher Scientific, Danone, Mead Johnson, Nutricia and consultancy/lecture fees from Meda, Thermofisher Scientific and ALK-Abello. RF has participated in expert panels for Nutricia, spoken for Stallergenes at educational meeting and has received educational sponsorship from ALK Abello. NS is on the Advisory Board for Mead-Johnson. LAvdP received conference fees from Nutricia.

Provenance and peer review

Commissioned; externally peer reviewed.

REFERENCES


38 Church MK, Maurer M. H(1)-antihistamines and urticaria: how can we predict the best drug for our patient? [Review]. **Clin Exp Allergy** 2012;42:1423–9.


